Bessemer Group
AMPH icon

Bessemer Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bessemer Group’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Sell
121,345
-701
-0.6% -$14.1K ﹤0.01% 813
2026
Q1 		$2.39M Buy
122,046
+1,156
+1% +$28.3K ﹤0.01% 774
2025
Q4 		$3.24M Buy
120,890
+120,747
+84,438% +$3.11M 0.01% 615
2025
Q3 		$4K Sell
143
-57
-29% -$1.47K ﹤0.01% 2169
2025
Q2 		$5K Sell
200
-361
-64% -$8.96K ﹤0.01% 2001
2025
Q1 		$17K Sell
561
-488,069
-100% -$15.6M ﹤0.01% 1586
2024
Q4 		$18.1M Buy
488,630
+11,609
+2% +$531K 0.03% 268
2024
Q3 		$23.1M Buy
477,021
+10,793
+2% +$474K 0.04% 239
2024
Q2 		$18.6M Buy
466,228
+70,287
+18% +$2.91M 0.03% 255
2024
Q1 		$17.4M Buy
395,941
+69,968
+21% +$3.61M 0.03% 251
2023
Q4 		$20.2M Buy
325,973
+177,829
+120% +$9.34M 0.04% 220
2023
Q3 		$6.81M Buy
148,144
+147,824
+46,195% +$8.06M 0.02% 318
2023
Q2 		$18K Buy
320
+182
+132% +$8.07K ﹤0.01% 1534
2023
Q1 		$5K Buy
138
+24
+21% +$787 ﹤0.01% 1593
2022
Q4 		$3K Hold
114
– – ﹤0.01% 1704
2022
Q3 		$3K Sell
114
-48
-30% -$1.57K ﹤0.01% 1827
2022
Q2 		$6K Hold
162
– – ﹤0.01% 1465
2022
Q1 		$6K Buy
+162
New +$4.59K ﹤0.01% 1463
2020
Q3 		– Sell
-111,600
Closed -$2.51M – 1344
2020
Q2 		$2.51M Hold
111,600
– – 0.01% 426
2020
Q1 		$1.66M Buy
111,600
+900
+0.8% +$15.7K 0.01% 478
2019
Q4 		$2.13M Buy
110,700
+5,600
+5% +$107K 0.01% 546
2019
Q3 		$2.08M Buy
105,100
+6,600
+7% +$137K 0.01% 504
2019
Q2 		$2.08M Sell
98,500
-1,400
-1% -$29.3K 0.01% 522
2019
Q1 		$2.04M Buy
99,900
+29,400
+42% +$659K 0.01% 450
2018
Q4 		$1.4M Buy
70,500
+38,300
+119% +$755K 0.01% 493
2018
Q3 		$620K Buy
+32,200
New +$574K ﹤0.01% 703
2016
Q4 		– Sell
-9,400
Closed -$178K – 1930
2016
Q3 		$178K Buy
+9,400
New +$171K ﹤0.01% 996

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Bessemer Group's AMPH Position: Q2 2026 in Review

Bessemer Group reduced its Amphastar Pharmaceuticals (AMPH) stake by 0.57% in Q2 2026, selling an estimated $14.1K and leaving 121,345 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #813.

Bessemer Group first reported a position in AMPH in Q3 2016 and has held it in 27 quarters since. The position peaked at $23.1M in Q3 2024. 210 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Bessemer Group held 121,345 shares of Amphastar Pharmaceuticals worth $2.45M as of Q2 2026.
  • Bessemer Group sold 701 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $14.1K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #813 holding.
  • Bessemer Group first reported a position in Amphastar Pharmaceuticals in Q3 2016 and has held it in 27 quarters since.
  • Bessemer Group's Amphastar Pharmaceuticals position peaked at $23.1M in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.